Organon to present results from Phase 3 Adoring 1, Adoring 2 on Vtama cream

Organon (OGN) will present results from a post-hoc sub-analysis of pooled data from the Phase 3 Adoring 1 and Adoring 2 trials evaluating the efficacy and safety of Vtama cream versus vehicle in an oral session at the 2026 American Academy of Dermatology Annual Meeting in Denver, Colorado, on Saturday, March 28, 2026. Vtama cream is the only aryl hydrocarbon receptor agonist indicated for the treatment of both plaque psoriasis in adults and treatment of atopic dermatitis in adults and pediatric patients 2 years and older. Notable findings from the post-hoc pooled analysis of Adoring 1 and Adoring 2 comparing Vtama cream versus vehicle include: Significant improvements in vIGA-AD, EASI75, and PP-NRS response rates as early as week 1. Significant vIGA-AD response was observed, defined as clear or almost clear skin with a greater than or equal to2-grade improvement from baseline, as early as week 1 and continued through week 8. Significant EASI75 response was achieved as early as week 1 and continued through week 8. Significant itch improvement, defined as a greater than or equal to4-point reduction in PP-NRS score for patients with a baseline score of greater than or equal to4, was achieved as early as week 1 and continued through week 8. The vast majority of patients achieved any EASI improvement from baseline at week 8 with Vtama cream.